Furthermore, low-dose interleukin (IL)-2, which enhances regulatory T-cell expression, thus limiting chronic inflammation, has been proved to be safe and biologically effective in NSTE-ACS patients by the LILACS (Low-dose InterLeukin 2 in patients with stable ischemic heart disease and Acute Coronary Syndromes) study [54]. Here, IL2 is linked to acute coronary syndrome.